Developmental outcomes of Aicardi Goutières Syndrome (P4.6-044)

Laura Adang(Children's Hospital of Philadelphia), Adeline Vanderver(Children's Hospital of Philadelphia), Jessica Galli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Kyle Peer(Children's Hospital of Philadelphia), Jamie Koh(Children's Hospital of Philadelphia), Sarah Woidill(Children's Hospital of Philadelphia), Nicole Ulrick(Children's Hospital of Philadelphia), Francesco Gavazzi(Children's Hospital of Philadelphia), Elisa Fazzi(Centro Studi GISED), Valentina De Giorgis(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Julia Kramer-Golkinkoff(Neurology, Inc), Justine Shults(Children's Hospital of Philadelphia), Micaela De Simone(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Simona Orcesi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino)
Neurology
April 9, 2019
10.1212/wnl.92.15_supplement.p4.6-044
Cited by 0

Related Papers

Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study
|The Lancet Neurology|2013|441
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
|The Lancet Neurology|2020|326
Magnetic resonance imaging pattern recognition in hypomyelinating disorders
|Brain|2010|285
<i>GFAP</i> mutations, age at onset, and clinical subtypes in Alexander disease
|Neurology|2011|256
Fetal Myelomeningocele Repair: The Post-MOMS Experience at the Children's Hospital of Philadelphia
|Fetal Diagnosis and Therapy|2014|212